| Literature DB >> 34863199 |
Matthew Dunn1, Timothy Piatkowski2.
Abstract
BACKGROUND: Emerging research has suggested that the COVID-19 pandemic has had some impact on substance use patterns. The aim of the study was to conduct a rapid survey to assess the impact of COVID-19 on performance and image enhancing drug (PIED) use and training, and any subsequent negative physical or mental health outcomes.Entities:
Keywords: Anabolic–androgenic steroids; COVID-19; Exercise; Performance and image enhancing drug use; Steroids
Mesh:
Substances:
Year: 2021 PMID: 34863199 PMCID: PMC8642842 DOI: 10.1186/s12954-021-00571-8
Source DB: PubMed Journal: Harm Reduct J ISSN: 1477-7517
Participant characteristics and types of PIEDs used prior to lockdown
| Sample | Blast-Cruise | OR | 95% CI | |||
|---|---|---|---|---|---|---|
| ( | No ( | Yes ( | ||||
| Mean age | 26.69 | 27.56 | 26.37 | [.616] | - | n.s |
| Mean BMI | 26.20 | 25.27 | 26.20 | [1.779] | - | n.s |
| Mean percentage body fat | 15.00 | 15.60 | 15.13 | .119 | -0.5,0.6 | n.s |
| Competed in a bodybuilding show (%) | 11.7 | 94.5 | 86.7 | 0.4 | 0.1,3.5 | n.s |
| Heterosexual (%) | 95.0 | 94.5 | 95.4 | 1.3 | 0.1,15.1 | n.s |
| Injectable (%; | ||||||
| Testosterone | 70; 42 | 47.1 | 79.1 | 4.3 | 1.3,14.2 | 0.007 |
| Trenbolone | 28.3; 17 | 5.9 | 37.2 | 9.5 | 1.1,78.4 | 0.007 |
| Boldenone | 23.3; 14 | 11.8 | 27.9 | 2.9 | 0.5,14.7 | n.s |
| Drostanolone | 16.7; 10 | 5.9 | 20.9 | 4.2 | 0.5,36.4 | n.s |
| Stanazolol | 13.3; 8 | 6.3 | 14.0 | 2.6 | 0.3,23.3 | n.s |
| Nandrolone | 13.3; 8 | 11.8 | 16.3 | 1.5 | 0.3,7.8 | n.s |
| Methenolone | 5; 3 | 11.8 | 2.3 | 0.2 | 0.1,2.1 | n.s |
| Oral (%; | ||||||
| Oxandrolone | 28.3; 17 | 17.6 | 32.6 | 2.3 | 0.6,9.1 | n.s |
| Metandienone | 25; 15 | 17.6 | 27.9 | 1.8 | 0.4,7.4 | n.s |
| Oxymetholone | 13.3; 8 | 5.9 | 16.3 | 3.1 | 0.4,27.4 | n.s |
| Stanazolol | 11.7; 7 | 5.9 | 16.3 | 3.1 | .4,27.4 | n.s |
| Mesterolone | 8.3; 5 | 5.9 | 9.3 | 1.6 | 0.2,15.8 | n.s |
| Chlorodehydromethyltestosterone | 1.7; 1 | 5.9 | 0.0 | 0.3 | 0.2,0.4 | n.s |
| Fluoxymesterone | 1.7; 1 | 0.0 | 2.3 | 0.7 | 0.6,0.8 | n.s |
| Other PIEDs (%; | ||||||
| Clenbuterol | 16.7; 10 | 5.9 | 20.9 | 4.2 | 0.5,36.4 | n.s |
| Human-growth-hormone | 10; 6 | 5.9 | 11.6 | 2.1 | 0.2,19.5 | n.s |
| Peptides | 10; 6 | 11.8 | 9.3 | 0.8 | 0.1,4.6 | n.s |
| Insulin | 8.3; 5 | 5.9 | 9.3 | 1.6 | 0.2,15.8 | n.s |
| Prohormones | 8.3; 5 | 0.0 | 11.6 | 0.7 | 0.6,0.8 | n.s |
| Selective-androgen-receptor-modulators | 6.7; 4 | 5.9 | 7.0 | 1.2 | 0.1,12.4 | n.s |
| T3 | 5; 3 | 5.9 | 4.7 | 0.8 | 0.1,9.2 | n.s |
| Insulin-like-growth-factor-1 | 5; 3 | 5.9 | 4.7 | 0.8 | 0.1,9.2 | n.s |
Specific p values available from authors on request
Exercise and PIED use patterns pre-lockdown and during lockdown
| Variable | Sample | Blast Cruise | OR [t] | 95% CI | ||
|---|---|---|---|---|---|---|
| ( | No ( | Yes ( | ||||
| Pre-lockdown (%; | ||||||
| Weight-training | 98.3; 59 | 100 | 95.4 | 1.4 | 1.2,1.7 | n.s |
| Train at a gym | 95.0; 57 | 88.2 | 95.4 | 5.6 | 0.5,6.3 | n.s |
| Home gym | 25; 15 | 5.9 | 32.6 | 7.7 | 0.9,64.3 | 0.001 |
| Train by self | 91.7; 55 | 100 | 88.4 | 1.4 | 1.2,1.7 | n.s |
| During lockdown (%; | ||||||
| Weight-training | 83.3; 50 | 88.2 | 88.4 | 1.4 | 1.3,2.4 | n.s |
| Train at a gym | 88.9; 32 | 100 | 85.7 | 1.3 | 1.1,1.6 | n.s |
| Home gym | 35; 21 | 29.4 | 37.3 | 1.4 | 0.4,4.8 | n.s |
| Train by self | 80.6; 29 | 100 | 75.0 | 1.4 | 1.1,1.7 | n.s |
| PIED use during lockdown (%; | ||||||
| PIEDs use changed | 45.0; 27 | 23.5 | 34.9 | 1.7 | 0.5,6.3 | n.s |
| Change due to access issues | 60.0; 36 | 58.8 | 60.5 | 1.1 | 0.3,3.6 | n.s |
| PIEDs precautions (e.g. more swabbing) | 40.0; 24 | 52.9 | 34.9 | 0.5 | 0.2,1.5 | n.s |
| PIEDs Cessation | 16.7; 10 | 70.6 | 30.2 | 0.2 | 0.1,0.6 | 0.002 |
| If ceased, used post-cycle therapy | 13.3; 8 | 11.8 | 4.7 | 2.6 | 0.2,7.7 | n.s |
| If ceased, had negative health effects | 5.0; 3 | 11.8 | 2.3 | 8.5 | 1.5,6.2 | 0.003 |
| Issues in accessing harm reduction | 46.7; 28 | 52.9 | 44.2 | 0.7 | 0.2,2.2 | n.s |
| Acquisition of PIEDs online | 51.7; 31 | 41.2 | 55.8 | 1.8 | 0.6,5.6 | n.s |
Specific p values available from authors on request